California man sentenced for brothel operation in eastern Va., Boston
BOSTON, Ma. (DC News Now) — A California man was sentenced in federal court in Boston for his involvement in a sophisticated high-end brothel in the eastern Virginia and Boston area, according to a release.
70-year-old James Lee was sentenced to more than two years in prison with three years of supervised release.
Woman shot at CIA headquarters in McLean charged with DUI; court documents
From at least January 2022 through November 2023, James Lee conspired with two others, identified as Han Lee and Junmyung Lee, to operate a prostitution network with multiple brothels in eastern Virginia and Boston.
James Lee rented several high-end apartments as the sole tenant to use as brothel locations, using his own name as well as fraudulent or stolen identities. Han Lee paid James Lee around $1,000 per month for each active lease.
Han Lee also served as a liaison between the women working in the units and the property managers by fielding calls and coordinating any issues that arose relating to maintenance and inspections.
James Lee and his co-conspirators knowingly conspired with one another to launder the proceeds of the prostitution network by concealing that the money was derived from the prostitution conspiracy.
James Lee was arrested and charged in November 2023 with his co-defendants. The defendants were subsequently indicted by a federal grand jury in February 2024.
Onlookers rescue fawn found on roadway in Carroll County
In February of 2025, James Lee pleaded guilty to one count of conspiracy to persuade, induce, entice and coerce one or more individuals to travel in interstate or foreign commerce to engage in prostitution; one count of money laundering conspiracy; and one count of wire fraud.
James Lee was also sentenced for his involvement in fraudulently obtaining over $580,000 in COVID-19 relief funds. The Court ordered restitution in the amount of $569,123 in connection with the fraudulently obtained COVID-19 funds and a money judgment of $63,000 related to the proceeds earned by the defendant as a result of the prostitution conspiracy.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Defense attorney for suspect in Aliza Sherman's murder hints at strategy: I-Team
CLEVELAND (WJW) – The accused killer of Aliza Sherman was in court on Tuesday for his first pretrial and his attorney is now hinting on plans to fight the charges. Gregory Moore, 51, is accused of killing Sherman in 2013. Her murder went unsolved for 12 years. Moore was indicted on several charges, including aggravated murder, on May 2. His defense attorney, Jon Paul Rion, is questioning why prosecutors are filing the charges now. 'The delay in this case is of concern,' Rion said. 'It is not clear if there is any new evidence.' What is the Prenatal Equal Protection Act? New bill would effectively ban abortion in Ohio Prosecutors allege the murder happened because Moore was not prepared to take her case to trial. Prosecutors have also said there is technology available now that was not available more than a decade ago when the murder happened. 'You have a due process right to have a trial within a reasonable period of time, when all the witnesses and evidence are available for both sides,' Rion said. 'If there are material witnesses or other evidence no longer in existence that could adversely affect the defendant, in this case Greg Moore, the court has to look if it's even fair to have a trial.' Cleveland Clinic to extend hours for surgeries, specialty appointments at many NE Ohio locations Sherman's estranged husband died last year. Prosecutor's have said he was not a suspect in the case. Moore remains jailed on a $2 million bond but his attorney said he may file a motion asking for a bond reduction. Moore is due back in court next month. His trial date has been set for March 30. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Wire
4 hours ago
- Business Wire
J.B. Poindexter & Co., Inc. Acquires Ambulance Manufacturing Leader Demers Braun Crestline Medix
HOUSTON--(BUSINESS WIRE)--J.B. Poindexter & Co., Inc. (JBPCO), a privately held North American manufacturing leader serving the commercial vehicle and specialty manufacturing industries, today announced the acquisition of Demers Braun Crestline Medix (DBCM). 'Our acquisition of DBCM aligns with JBPCO's long-term vision—building a platform of industry-leading companies with a shared commitment to quality, innovation, and customer service,' said John Poindexter, CEO and Chairman of JBPCO. Share Headquartered in Beloeil, Quebec (Canada), DBCM is one of North America's largest ambulance manufacturers with a strong presence across the U.S. and Canadian markets. Known for advanced innovation and paramedic-driven design, DBCM has delivered more than 70,000 units to over 40 countries and employs more than 1,500 team members across its operations. 'Our acquisition of DBCM aligns with JBPCO's long-term vision—building a platform of industry-leading companies with a shared commitment to quality, innovation, and customer service,' said John Poindexter, CEO and Chairman of JBPCO. 'As JBPCO celebrates its 40th anniversary, and each of the DBCM brands celebrates decades of dedication in the emergency vehicle industry, we are proud to bring together more than 500 years of combined manufacturing excellence across our portfolio of companies. DBCM has built a solid foundation, and we look forward to investing in its future, supporting the team, enhancing the products, and unlocking new opportunities for growth.' Demers recently launched its 11 th -generation ambulance platform and continues to set the bar in safety, design, and performance with paramedic-centric features like the FX Care Module. As part of JBPCO, the Company will continue to operate with brand autonomy while benefiting from expanded resources, shared capabilities, and a culture that values team member contributions. 'Joining JBPCO is a major milestone for our organization and our team,' said Alain Brunelle, CEO of Demers Braun Crestline Medix. 'We are united by a mission to improve lives, one relationship and one vehicle at a time—and this partnership ensures we can continue doing just that, with even greater scale and support.' JBPCO's total revenue will reach $3 billion with this acquisition, reinforcing its role as a cornerstone in the commercial and specialty vehicle manufacturing space—from last-mile delivery and work trucks to emergency response vehicles. About J.B. Poindexter & Co., Inc. J.B. Poindexter & Co., Inc. (JBPCO) is a privately held, diversified manufacturing company providing best-in-class commercial automotive and industrial solutions. JBPCO owns and operates a portfolio of leading business units including Morgan Truck Body, LLC; Morgan Olson, LLC; The Reading Truck Group, LLC; Truck Accessories Group, LLC d/b/a LEER Group; Masterack, LLC; EFP, LLC; Federal Eagle, LLC; and EAVX. JBPCO is headquartered in Houston, Texas and with the acquisition of DBCM, now employs more than 10,000 team members across North America. For more information, visit or connect on LinkedIn. Demers Braun Crestline Medix is one of North America's largest ambulance manufacturers, with a legacy of over 175 years across its four leading brands. Headquartered in Beloeil, Quebec, and operating in both Canada and the United States, the company designs and manufactures ambulances that meet the evolving needs of emergency service providers. Its brands—Demers, Braun, Crestline, and Medix—have delivered over 70,000 units in more than 40 countries. To learn more, visit and
Business Upturn
4 hours ago
- Business Upturn
INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the 'Class Period'), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc. , No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided investors with material information concerning Rocket Pharmaceuticals' Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events, including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders, according to the complaint. The Rocket Pharmaceuticals class action lawsuit further alleges that on May 27, 2025, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event, ultimately, death, while enrolled in the study following a substantive amendment to the protocol that Rocket Pharmaceuticals failed to disclose to investors at the time management made the revision. On this news, the price of Rocket Pharmaceuticals stock fell, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Rocket Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Rocket Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Rocket Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
